Plus Therapeutics Inc

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Plus Therapeutics advances trials, secures funding, and expands diagnostics

Plus Therapeutics demonstrates strong financial and operational progress with successful funding, grants, and trial advancements.
Strategic additions to the management team and diagnostic capabilities enhance the company's expertise and market positioning.
Challenges in financial management, regulatory processes, and dosing strategies require careful navigation for sustained growth and success.
Opportunities lie in FDA feedback, commercial launches, collaborations, and positive trial outcomes for future growth and market impact.

Plus Therapeutics Inc (PSTV) reports clinical progress amidst financial challenges

Plus Therapeutics Inc (PSTV) made significant clinical advancements in Q2 2024, while facing financial challenges. The company's strengths include positive trial results and supportive conference data, with opportunities for growth through expanded capabilities and funding access.

Plus Therapeutics progresses in leptomeningeal metastases program with strong financial backing

Plus Therapeutics is advancing promising treatments for leptomeningeal metastases with encouraging clinical data and FDA support.
Financially, the company is well-positioned with a solid cash balance, expected grant revenue, and access to diverse funding sources.
Strategic focus on upcoming events, milestones, and product launches underscores the company's commitment to innovation and growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vinco Ventures

Palisade Bio

Here's what you need to know about buying penny stocks on August 18th The post Cheap Penny Stocks to Buy Now? 3 To Watch in August appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Cheap Penny Stocks to Buy Now? 3 To Watch in August

Funding from the Cancer Prevention and Research Institute of Texas (CPRIT), the second largest global public funder of cancer research, will support the majority of the development costs of 186 RNL for leptomeningeal metastases.

Plus Therapeutics Awarded $17.6 Million from State of Texas

Source: Shutterstock / PopTika Plus Therapeutics (NASDAQ: PSTV ) stock is climbing higher on Monday after the company revealed a stock buyback program. According to a press release from the company, its Board of Directors approved the repurchase of up to $2 million worth of PSTV stock.

Why Is Plus Therapeutics (PSTV) Stock Up 38% Today?

AUSTIN, Texas, Aug. 13, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, yesterday presented positive data from two ongoing clinical trials of its lead investigational drug, Rhenium-186 Nanoliposome (186RNL), in the treatment of recurrent glioblastoma (GBM) and leptomeningeal metastases (LM) at the 2022 Annual Conference on CNS Clinical Trials and Brain Metastases. The conference is co-sponsored by the Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO) and is being held August 12-13, 2022 in Toronto, Canada.

Plus Therapeutics Presents Positive Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases

AUSTIN, Texas, July 28, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present data from two ongoing clinical trials for recurrent glioblastoma and leptomeningeal metastases at the 2022 Annual Conference on CNS Clinical Trials and Brain Metastases, co-sponsored by the Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO), being held August 12-13, 2022 in Toronto, Canada.

Plus Therapeutics to Present Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases

AUSTIN, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Norman LaFrance, M.D., Chief Medical Officer and SVP will give a presentation on the Company's lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), and share updates on the U.S. ReSPECT clinical trials at the inaugural Targeted Radiopharmaceuticals Summit, organized by Hanson Wade, being held July 26-28, 2022 at the Boston Park Plaza in Boston, Massachusetts.

Plus Therapeutics to Present at Inaugural Targeted Radiopharmaceuticals Summit

Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q2 2022 Results Conference Call July 21, 2022 5:00 PM ET Company Participants Dr. Marc Hedrick - President and Chief Executive Officer Dr. Norman LaFrance - Chief Medical Officer Andrew Sims - Chief Financial Officer Conference Call Participants Michael Rabinowitz - Maxim Group Ed Woo - Ascendiant Capital Operator Good afternoon, ladies and gentlemen. Welcome to the Plus Therapeutics Second Quarter 2022 Results Call.

Plus Therapeutics, Inc. (PSTV) CEO Dr. Marc Hedrick on Q2 2022 Results - Earnings Call Transcript

Completed enrollment of Cohort 1 in ReSPECT-LM Phase 1/2a dose escalation trial of 186 RNL for Leptomeningeal Metastases

Plus Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

AUSTIN, Texas, July 13, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report second quarter 2022 financial results on Thursday, July, 21, 2022, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.

Plus Therapeutics to Announce Second Quarter 2022 Financial Results and Host Conference Call on July 21, 2022

Completes technology transfer and initiates cGMP manufacturing for critical Rhenium-186 NanoLiposome ( 186 RNL) drug product intermediate

Plus Therapeutics Successfully Completes Key Milestone for cGMP Manufacture of Lead Investigational Radiotherapeutic

Biocept

Biocept Inc (NASDAQ:BIOC) and Plus Therapeutics Inc have announced a comprehensive laboratory services agreement for Plus Therapeutics' ReSPECT-LM trial for the treatment of cancer in the membranes that surround the brain and spinal cord.  Under the multi-year agreement, Biocept's cerebrospinal fluid (CSF) assay CNSide1 will be employed in Plus Therapeutics' ReSPECT-LM Phase 1/2a dose-escalation clinical trial of Rhenium-186 NanoLiposome (186RNL) for the treatment of patients with leptomeningeal metastases (LM).

Biocept enters into comprehensive laboratory services agreement with Plus Therapeutics for cancer trial

Biocept's CNSide™ assay provides a highly sensitive method to assess and quantify tumor cell burden in leptomeningeal metastasis (LM) of the central nervous system

Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial

Rhenium-186 NanoLiposome (186RNL) Targeted Radiotherapeutic successfully delivered without dose limiting toxicities in initial cohort

Plus Therapeutics Completes Enrollment of Cohort 1 ReSPECT-LM Phase 1/2a Trial

Data validates continued high radiation absorbed of 186 RNL in escalating doses to treat glioblastoma, maintaining safety and limiting brain and whole-body exposure

Plus Therapeutics Reports Positive Clinical Outcomes from ReSPECT-GBM Trial at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting

AUSTIN, Texas, May 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, will present virtually at the 2022 H.C. Wainwright Global Investment Conference being held May 23-26, 2022.

Plus Therapeutics to Present Virtually at the 2022 HC Wainwright Global Investment Conference

Creatd Inc

LiveOne

US crude oil futures traded higher this morning on Friday. Investors, meanwhile, focused on some notable insider trades.

3 Stocks Under $1 Insiders Are Aggressively Buying

AUSTIN, Texas, April 26, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, will present at the 2022 Q2 Investor Summit on Tuesday, May 3, 2022, at 12:30 p.m. ET at the Westin New York Grand Central, New York, N.Y.

Plus Therapeutics to Present at the 2022 Q2 Investor Summit

First patient dosed in ReSPECT-LM Phase 1/2a dose escalation trial of 186 RNL for leptomeningeal metastases

Plus Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

AUSTIN, Texas, April 19, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that it will discuss new data in an oral presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting, being held June 11-14, 2022, in Vancouver, British Columbia, Canada.

Plus Therapeutics Announces Oral Presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting

AUSTIN, Texas, April 14, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report first quarter 2022 financial results on Thursday, April, 21, 2022, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.

Plus Therapeutics to Announce First Quarter 2022 Financial Results and Host Conference Call on April 21, 2022

AUSTIN, Texas, April 08, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that the company will present a poster at the upcoming American Association for Cancer Research (AACR) 2022 Annual Meeting, which is being held April 8-13, 2022, in New Orleans, La., and virtually.

Plus Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting

Companies collaborate to design innovative registrational trial of 186 RNL for recurrent glioblastoma

Plus Therapeutics and Medidata Announce Expanded Clinical Trial Partnership

AUSTIN, Texas, March 03, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will sponsor and present an industry satellite symposium at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Therapeutics Conference, being held in-person March 10-12, 2022 at the Hyatt Regency, New Orleans, Louisiana.

Plus Therapeutics Announces Upcoming Participation at the 2022 SNMMI Therapeutics Conference

Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q4 2021 Results - Earnings Call Transcript

Initial plan to evaluate project feasibility, may lead to expanded partnership for clinical and regulatory implementation Initial plan to evaluate project feasibility, may lead to expanded partnership for clinical and regulatory implementation

News for Plus Therapeutics Inc Stock (PSTV)